FUJIFILM Biotechnologies

Discover a novel technology to standardize purification across a broad range of microbial proteins that accelerates and streamlines microbial workflows. This new technology addresses a key bottleneck in microbial bioprocessing, enabling predictable, scalable, and accelerated manufacturing of next-generation biologics. Download the white paper to learn more.

Accelerate microbial bioprocess development with proven strategies that shorten timelines. Learn practical methods to de-risk scale-up from gene to GMP without compromising quality whilst enabling rapid, confident progression to robust, scalable and commercially viable processes.

Downstream processing can be the cause of a bottleneck in manufacturing, particularly for complex biologics, leading to a need for simpler platform approaches. In this technical interview, we discuss solutions that are being deployed to address this complicated challenge and a new, more simplified approach for a diverse subset of non-mAb therapies.  

Discover the benefits of a global CDMO manufacturing strategy built for scale, speed and reliability

See how early supply chain engagement and continuous improvement reduce risk, accelerate tech transfer and time-to-market, and ensure reliable supply for customers and patients—download the white paper to learn more.

Biologics manufacturing is shifting toward integrated ecosystems that align clinical and commercial needs within a unified operational model. Learn how to deliver speed, flexibility, and lifecycle efficiency from early clinical supply to high-volume commercial production.

Webinar Date/Time: Wed, Jun 24, 2026 11:00 AM EDT

This white paper offers concise, practical guidance for biopharma teams outsourcing Process Characterization (PC) to strengthen CMC packages and accelerate commercialization.

Microbial cell culture processes are diverse and difficult to harmonize, however, with a new microbial purification platform, downstream processes are streamlined. Applicable for use in E. coli and P. pastoris, this microbial purification platform utilizes a novel scarless protease to reduce purification steps, accelerating the journey from PD to GMP.

Discover how a “Predict-First” approach uses AI-driven in silico models to de-risk mAb development. See real-case results and a manufacturability scoring framework that accelerates decisions and speeds therapies to market.

Case study showcasing accelerated PPQ for an E. coli–expressed orphan therapy, achieving three PPQ batches in 18 months through high-compliance manufacturing.

Discover how a robust platform enables fast, high-quality bispecific antibody production by optimizing gene ratios, CLD, and analytics for purity and yield.

Discover the future of microbial expression with a platform that optimizes strain selection, expression systems, and purification methods, providing actionable insights in just eleven weeks.

This white paper explains the benefits and challenges of microbial-based fermentation for biologics, highlighting why processes often need to be custom-built for each molecule. Outlining a streamlined, cost-effective path that accelerates development from strain selection through tox material and early GMP, to reach IND and first-in-human trials faster.

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.